• 1
    Ipsen H, Wihl, JÅ, Nüchel, Petersen B, Løwenstein H. Specificity mapping of patients' IgE response towards the tree pollen major allergens Aln g 1, Bet v 1 and Cor a I. Clin Exp Allergy 1992; 22: 3919.
  • 2
    Ipsen H, Hansen OC. The NHU-terminal amino acid sequence of the immunochemically partially identical major allergens of alder (Alnus glutinosa) Aln g 1, birch (Betula vermcosa) Bet v 1. hornbeam (Carpinus betulus) Car b 1 and oak (Quercus alba) Que a 1 pollens. Mol Immunol 1991: 28: 127988.
  • 3
    Mosbech H, ósslerballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 43: 5239.
  • 4
    Hedlin G, Heilborn H, Lilja O, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96: 87985.
  • 5
    Ipsen H, Schwartz B, Wihl, JÅ, et al. Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy. Allergy 1988; 43: 3707.
  • 6
    Nüchel Petersen B, Janniche H, Munch EP, et al. Immunotherapy with partially purified and standardised tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43: 35362.
  • 7
    Wihl, JÅ, Ipsen, H, Nüchel Petersen B, Munch EP, Janniche H, Løwenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43: 3639.
  • 8
    Kleine-Tebbe J, Eickholt M, Gätjen M, Brunnée T, O'Connor A, Kunkel G. Comparison between Magic Lite and CAP System: two automated specific IgE antibody assays. Clin Exp Allergy f992; 22: 47584.
  • 9
    Rak S, Löwhagen O, Venge R. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; Sept 47080.
  • 10
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991: 302: 2659.
  • 11
    Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50: 40513.
  • 12
    østerballe O. Immunotherapy with grass pollen major allergens. Clinical results from a prospective 3-year double-blind study. Allergy 1982; 37: 37988.
  • 13
    Olsen OT, Frølund J, Heinig L, Jacobsen L, Gerner Svendsen U. A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/Betula verrucosa. Allergol Immunopathol (Madr) 1995; 23(2): 738.
  • 14
    Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat and dog dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991: 5(87): 95564.
  • 15
    Valovirta E, Koivikko A, Vanto T, Viander M, Ingemann L. Immunotherapy in allergy to dog: a double blind clinical study. Ann Allergy 1984; 53: 858.
  • 16
    van Metre TE, Marsh DG, Adkinson NF, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82(6): 105568.
  • 17
    Mailing H-J, Djurup R, Søndergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on .in vivo and in vitro parameters. Allergy 1985; 40: 37383.
  • 18
    Mosbech H, Mailing H-J, Biering I, et al. Immuntherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986; 41: 95103.
  • 19
    Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardised, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 3(91): 70922.
  • 20
    McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG and IgG subclasses. J Allergy Clin Immunol 1990; 86(1): 52131.
  • 21
    Wahn U, Schweter C, Lind P, Løwenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988; 82: 36070.
  • 22
    Dreborg S, Agrell B, Foucard T, Kjellman M, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children using a purified and standardized Cladosporium herbarum preparation. Allergy 1986; 41: 13140.
  • 23
    Mailing H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. Allergy 1986; 41: 50719.
  • 24
    Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 64451.
  • 25
    Allergenic pollen and pollinosis in Europe. In: D'Amato G, Spieksma FTM, Bonini S. Allergenic pollen and pollinosis in Denmark. Blackwell Scientific, 1991: 1518.
  • 26
    Mailing H-J, Weeke B, editors. EAACI Position Paper. Immunotherapy. Allergy 1993; 48 Suppl 14: 935.
  • 27
    Aalberse RC, van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993; 48: 55969.